NEW YORK–(BUSINESS WIRE)–Bragar Eagel & Squire, P.C. announces that a class action lawsuit has
been filed in the U.S. District Court for the Northern District of
Georgia on behalf of all persons or entities who purchased or otherwise
acquired MiMedx Group, Inc. (NASDAQ: MDXG) securities between March 7,
2013 and February 19, 2018 (the “Class Period”). Investors have until
April 25, 2018 to apply to the Court to be appointed as lead plaintiff
in the lawsuit.

On February 20, 2018, MiMedx announced that it will postpone the release
of its financial results, as well as the filing of its Form 10-K, for
the year ended December 31, 2017. This raised further concerns over the
reports of short sellers who had accused MiMedx of “serious and
pervasive fraud.” Following this news, the stock price of MiMedx fell
$5.72 per share, or over 39%, to close at $8.75 per share on February
20, 2018

The complaint alleges that throughout the Class Period, Defendants made
false and/or misleading statements and/or failed to disclose that
(i) MiMedx was engaged in a “channel-stuffing” scheme designed to
inappropriately recognize revenue that had not yet been realized;
(ii) the Company lacked adequate internal controls over financial
reporting; and (iii) that as a result of the foregoing, MiMedx’s
publicly disseminated financial statements were materially false and
misleading.

If you purchased or otherwise acquired MiMedx securities and suffered a
loss, continue to hold shares purchased prior to the Class Period, have
information, would like to learn more about these claims, or have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Brandon Walker or Melissa
Fortunato by email at [email protected],
or telephone at (212) 355-4648, or by filling
out this contact form. There is no cost or obligation to you.

For more information, please visit .